TY - JOUR
T1 - Substrates and potential therapeutics of ventricular arrhythmias in heart failure
AU - Zhang, Dongze
AU - Tu, Huiyin
AU - Wadman, Michael C.
AU - Li, Yu Long
N1 - Funding Information:
This work was supported by National Heart, Lung, and Blood Institute Grant 1R01HL137832-01 to Y.L. Li.
Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2018/8/15
Y1 - 2018/8/15
N2 - Heart failure (HF) is a clinical syndrome characterized by ventricular contractile dysfunction. About 50% of death in patients with HF are due to fetal ventricular arrhythmias including ventricular tachycardia and ventricular fibrillation. Understanding ventricular arrhythmic substrates and discovering effective antiarrhythmic interventions are extremely important for improving the prognosis of patients with HF and reducing its mortality. In this review, we discussed ventricular arrhythmic substrates and current clinical therapeutics for ventricular arrhythmias in HF. Base on the fact that classic antiarrhythmic drugs have the limited efficacy, side effects, and proarrhythmic potentials, we also updated some therapeutic strategies for the development of potential new antiarrhythmic interventions for patients with HF.
AB - Heart failure (HF) is a clinical syndrome characterized by ventricular contractile dysfunction. About 50% of death in patients with HF are due to fetal ventricular arrhythmias including ventricular tachycardia and ventricular fibrillation. Understanding ventricular arrhythmic substrates and discovering effective antiarrhythmic interventions are extremely important for improving the prognosis of patients with HF and reducing its mortality. In this review, we discussed ventricular arrhythmic substrates and current clinical therapeutics for ventricular arrhythmias in HF. Base on the fact that classic antiarrhythmic drugs have the limited efficacy, side effects, and proarrhythmic potentials, we also updated some therapeutic strategies for the development of potential new antiarrhythmic interventions for patients with HF.
KW - Antiarrhythmic drugs
KW - Catheter ablation
KW - Heart failure
KW - Ventricular arrhythmia
KW - Ventricular arrhythmic substrate
UR - http://www.scopus.com/inward/record.url?scp=85049304742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049304742&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2018.06.024
DO - 10.1016/j.ejphar.2018.06.024
M3 - Article
C2 - 29940156
AN - SCOPUS:85049304742
SN - 0014-2999
VL - 833
SP - 349
EP - 356
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
ER -